✨
AI Summary
- Dapagliflozin reduces cardiovascular death or HF worsening regardless of setting.
- A meta-analysis of DAPA-HF, DELIVER, and DAPA-ACT-HF trials showed this.
- The drug demonstrated substantial improvements in prior cardiovascular death risk.